BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 15899803)

  • 1. Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer.
    Bradley SV; Oravecz-Wilson KI; Bougeard G; Mizukami I; Li L; Munaco AJ; Sreekumar A; Corradetti MN; Chinnaiyan AM; Sanda MG; Ross TS
    Cancer Res; 2005 May; 65(10):4126-33. PubMed ID: 15899803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival.
    Rao DS; Hyun TS; Kumar PD; Mizukami IF; Rubin MA; Lucas PC; Sanda MG; Ross TS
    J Clin Invest; 2002 Aug; 110(3):351-60. PubMed ID: 12163454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Huntingtin interacting protein 1 is a novel brain tumor marker that associates with epidermal growth factor receptor.
    Bradley SV; Holland EC; Liu GY; Thomas D; Hyun TS; Ross TS
    Cancer Res; 2007 Apr; 67(8):3609-15. PubMed ID: 17440072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant Huntingtin interacting protein 1 in lymphoid malignancies.
    Bradley SV; Smith MR; Hyun TS; Lucas PC; Li L; Antonuk D; Joshi I; Jin F; Ross TS
    Cancer Res; 2007 Sep; 67(18):8923-31. PubMed ID: 17875735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model.
    Schmittgen TD; Zakrajsek BA; Hill RE; Liu Q; Reeves JJ; Axford PD; Singer MJ; Reed MW
    Prostate; 2003 Jun; 55(4):308-16. PubMed ID: 12712410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
    Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
    Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.
    Haram KM; Peltier HJ; Lu B; Bhasin M; Otu HH; Choy B; Regan M; Libermann TA; Latham GJ; Sanda MG; Arredouani MS
    Prostate; 2008 Oct; 68(14):1517-30. PubMed ID: 18668517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignancy arising in seminal vesicles in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Yeh IT; Reddick RL; Kumar AP
    Prostate; 2009 May; 69(7):755-60. PubMed ID: 19170049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model.
    Raina K; Blouin MJ; Singh RP; Majeed N; Deep G; Varghese L; Glodé LM; Greenberg NM; Hwang D; Cohen P; Pollak MN; Agarwal R
    Cancer Res; 2007 Nov; 67(22):11083-91. PubMed ID: 18006855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model.
    Hsieh CL; Xie Z; Yu J; Martin WD; Datta MW; Wu GJ; Chung LW
    Prostate; 2007 May; 67(7):685-91. PubMed ID: 17342752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-Methoxyestradiol inhibits prostate tumor development in transgenic adenocarcinoma of mouse prostate: role of tumor necrosis factor-alpha-stimulated gene 6.
    Garcia GE; Wisniewski HG; Lucia MS; Arevalo N; Slaga TJ; Kraft SL; Strange R; Kumar AP
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):980-8. PubMed ID: 16467113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Huntingtin Interacting Protein 1 mutations lead to abnormal hematopoiesis, spinal defects and cataracts.
    Oravecz-Wilson KI; Kiel MJ; Li L; Rao DS; Saint-Dic D; Kumar PD; Provot MM; Hankenson KD; Reddy VN; Lieberman AP; Morrison SJ; Ross TS
    Hum Mol Genet; 2004 Apr; 13(8):851-67. PubMed ID: 14998932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic and preventive effect of RRR-alpha-vitamin E succinate on prostate cancer via induction of insulin-like growth factor binding protein-3.
    Yin Y; Ni J; Chen M; DiMaggio MA; Guo Y; Yeh S
    Clin Cancer Res; 2007 Apr; 13(7):2271-80. PubMed ID: 17404112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of a serum tumor marker for preclinical trials of mouse prostate cancer models.
    Huizen IV; Wu G; Moussa M; Chin JL; Fenster A; Lacefield JC; Sakai H; Greenberg NM; Xuan JW
    Clin Cancer Res; 2005 Nov; 11(21):7911-9. PubMed ID: 16278416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disruption of arginase II alters prostate tumor formation in TRAMP mice.
    Mumenthaler SM; Rozengurt N; Livesay JC; Sabaghian A; Cederbaum SD; Grody WW
    Prostate; 2008 Oct; 68(14):1561-9. PubMed ID: 18663728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired prostate tumorigenesis in Egr1-deficient mice.
    Abdulkadir SA; Qu Z; Garabedian E; Song SK; Peters TJ; Svaren J; Carbone JM; Naughton CK; Catalona WJ; Ackerman JJ; Gordon JI; Humphrey PA; Milbrandt J
    Nat Med; 2001 Jan; 7(1):101-7. PubMed ID: 11135623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-CoA racemase.
    Wang J; Weng J; Cai Y; Penland R; Liu M; Ittmann M
    Prostate; 2006 Jun; 66(8):847-57. PubMed ID: 16491480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An investigation of the effects of late-onset dietary restriction on prostate cancer development in the TRAMP mouse.
    Suttie AW; Dinse GE; Nyska A; Moser GJ; Goldsworthy TL; Maronpot RR
    Toxicol Pathol; 2005; 33(3):386-97. PubMed ID: 15805078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. beta1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts.
    Goel HL; Breen M; Zhang J; Das I; Aznavoorian-Cheshire S; Greenberg NM; Elgavish A; Languino LR
    Cancer Res; 2005 Aug; 65(15):6692-700. PubMed ID: 16061650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.